Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 18

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 18
---
 plasmid-based
DNA manufacturing technologies that have supplied the DNA used in biotherapeutics for the past 40 years. LineaDNA can be quickly produced
in batches ranging from milligram to grams under a variety of controlled manufacturing processes including research use only (RUO), good
laboratory practices (GLP) and good manufacturing practices (GMP).

We believe LineaDNA holds several important advantages
over existing cell-based plasmid DNA manufacturing platforms. Plasmid-based DNA manufacturing is based on the complex, costly and time-consuming
biological process of amplifying DNA in living bacterial cells. Once amplified, the DNA must be separated from the living cells and other
process contaminants via multiple rounds of purification, adding further complexity and costs. Unlike plasmid-based DNA manufacturing,
LineaDNA does not require living cells and instead amplifies DNA via the exponential enzymatic process of PCR. The LineaDNA platform is
simple, scalable and can rapidly produce large quantities of DNA with minimal purification steps.

Preclinical studies conducted by the Company have shown that
LineaDNA is substitutable for plasmid DNA in numerous biotherapeutic applications, including:

| · | DNA vaccines; |

| · | DNA templates to produce RNA, including mRNA therapeutics; |

| · | adoptive cell therapy (CAR-T) manufacturing; and |

| · | homology-directed repair (HDR)-mediated gene editing. |

| S-8 |

Further, we believe that LineaDNA is also substitutable
for plasmid DNA in the following nucleic acid-based therapies:

| · | viral vector manufacturing for in vivo and ex vivo gene editing; |

| · | clustered regularly interspaced short palindromic repeats-mediated gene therapy (CRISPR); and |

| · | non-viral gene therapy. |

LineaRNAP

mRNA therapeutics are produced via a process called
in vitro transcription (“IVT”) that requires a DNA template and RNAP as starting materials. Typically, the RNAP is derived
from the T7 bacteriophage (“WT-T7”). LineaRNAP is a patented next generation WT-T7-based RNAP engineered with a proprietary
DNA-binding domain resulting we believe in high mRNA yields, increased mRNA integrity and reduced double-stranded RNA (dsDNA) contamination
as compared to conventional WT-T7. LineaRNAP is engineered for use either as a direct replacement for WT-T7 in conventional IVT workflows
or with chemically modified LineaDNA templates